Strategic Analysis of Johnson & Johnson Pharmaceutical Division
This paper presents a strategic analysis of Johnson & Johnson's pharmaceutical division, drawing on PEST analysis, Porter's Five Forces, and SWOT analysis to evaluate the company's competitive position. The paper provides an overview of Johnson & Johnson's product lines and revenue trends, followed by a review of the broader U.S. pharmaceutical industry. It examines strategic definitions from leading scholars, identifies key internal and external environmental factors, and highlights persistent challenges including high R&D costs and intensifying competition. The paper concludes with recommendations for market expansion into China and India as a means of reducing operational costs and capturing emerging market growth.
- Company Overview: J&J's divisions, products, and recent revenue trends
- Industry Overview and Strategic Issues: U.S. pharma market size, growth, and competitive pressures
- Definitions of Strategy Applied to Johnson & Johnson: Scholarly strategy definitions linked to J&J practice
- Current Strategy: PEST Analysis, Porter's Five Forces, and SWOT Analysis: Three-framework environmental and competitive assessment
- Strategic Gaps and Recommendations: China market entry and cost reduction strategies
- Conclusion: Summary of findings and strategic recommendations
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Applies three well-established strategic frameworks — PEST, Porter's Five Forces, and SWOT — in sequence, giving the analysis both breadth and structure.
- Grounds abstract strategy concepts in concrete financial figures (e.g., revenue declines from $74.3B to $70B, R&D spending of $9B in 2015), making the argument tangible and verifiable.
- Connects multiple scholarly definitions of strategy to the specific context of Johnson & Johnson, demonstrating how theoretical frameworks translate into real business decisions.
Key academic technique demonstrated
The paper demonstrates triangulated strategic analysis — using three independent frameworks simultaneously to arrive at converging conclusions. Rather than relying on a single tool, the author cross-validates findings (e.g., high competition identified in both Porter's Five Forces and the SWOT threats) to build a more robust strategic recommendation. This technique is especially valuable in business and management writing, where no single model captures the full competitive environment.
Structure breakdown
The paper follows a phased structure: it opens with a company overview and industry context, then defines the concept of strategy using multiple scholarly sources before applying analytical frameworks. The frameworks section moves logically from macro-environmental factors (PEST) to industry-level forces (Porter) to internal capabilities (SWOT). Strategic gaps identified through analysis feed directly into the recommendations, ensuring the conclusion is evidence-driven rather than speculative. This funnel structure — broad context narrowing to specific actionable recommendations — is a model approach for applied business strategy papers.
Company Overview
Johnson & Johnson is an American multinational company producing a wide range of products that include consumer products, pharmaceutical products, and medical devices. Incorporated in 1889, Johnson & Johnson operates through three divisions: the Consumer Healthcare Division, the Medical Devices Division, and the Pharmaceutical Division. The pharmaceutical division produces different products to treat infectious diseases, neurological diseases, and oncological conditions. The immunology products the company produces include the antibodies Remicade and Simponi, which have been used for the treatment of ankylosing spondylitis, ulcerative colitis, Crohn's disease, and other disorders. In 2013, sales of two of these products accounted for 11.3% of total company revenue and 29% of the pharmaceutical division's revenue.
Despite the company's sustained success, Johnson & Johnson recorded a decline in total revenue between the 2014 and 2015 fiscal years. In 2014, the company's total revenue was $74.3 billion; however, total revenue declined to $70 billion by the end of the 2015 fiscal year. This decline also affected the pharmaceutical division, where revenue fell from $32.3 billion in 2014 to $31.4 billion in 2015. The objective of this study is to provide a strategic analysis of Johnson & Johnson's pharmaceutical division in order to assist the company in developing an effective strategy to achieve competitive market advantages.
References
Arnum, P.V. (2015). Outlook 2018: The current and future direction of the pharma industry. IMS Market Prognosis.
Gates, L.P. (2010). Strategic planning with critical success factors and future scenarios: An integrated strategic planning framework. Technical Report. Carnegie Mellon University, Software Engineering Institute.
KPMG (2011). Future pharma: Five strategies to accelerate the transformation of the pharmaceutical industry by 2020. KPMG LLP, UK.
PhRMA (2016). 2016 profile biopharmaceutical research industry. Washington, DC: PhRMA.
Porter, M. (1996). What is strategy? Harvard Business Review, 74(6).
Steiner, G. (2008). Strategic planning. New York: Simon and Schuster.
Tregoe, B.B., & Zimmerman, J.W. (1980). Top management strategy. New York: Simon & Schuster.
Create your account
Always verify citation format against your institution’s current style guide requirements.